81723-25-3

Basic information

• Product Name: ethyl N-(2,5-dimethoxycarbonyl phenyl)carbamate
• Synonyms: ethyl N-(2,5-dimethoxycarbonyl phenyl)carbamate
• CAS NO: 81723-25-3
• Molecular Weight: 281.265
• Mol File: 81723-25-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: ethyl N-(2,5-dimethoxycarbonyl phenyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl N-(2,5-dimethoxycarbonyl phenyl)carbamate(81723-25-3)
• EPA Substance Registry System: ethyl N-(2,5-dimethoxycarbonyl phenyl)carbamate(81723-25-3)

Safety Data

• Hazardous Substances Data: 81723-25-3(Hazardous Substances Data)

Upstream product

• 5372-81-6 dimethyl aminoterephthalate 
• 541-41-3 chloroformic acid ethyl ester 
• 120-61-6 1,4-benzenedicarboxylic acid dimethyl ester 
• 817-87-8 ethyl azidocarbonate 

Downstream Products

• 1134102-20-7 dimethyl 2-[(ethoxycarbonyl)amino]-5-nitroterephthalate 

Relevant articles and documents

3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE'S AND 3-SUBSTITUTED 1,3-PYRIMIDINONE'S FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson''s disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke- induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi''s syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.

FACILE SYNTHESIS OF N-SUBSTITUTED 1H-AZEPINE DERIVATIVES

The facile synthesis of N-sulphonyl and N-ethoxycarbonyl substituted 1H-azepines in high yields by the pressure-induced sulphonylnitrene insertion reaction or, in anhydrous solvents, the 1,3-dipolar azide addition reaction with aromatic substrates containing electron-withdrawing substituents (e.g. dimethyl terephthalate) are described.The probable sequences of reactions involved in the two cases have been indicated.